PQA has appointed 18 individuals to serve on a measure development technical expert panel (TEP) to support the development of a new health plan measure: Evidence of Guideline-Directed Medical Therapy in Persons with Heart Failure. This measure will assess the percentage of individuals with prescription claims for guideline-directed medical therapies for the treatment of heart failure.
PQA identified heart failure as a priority area for measure development in 2025. A PQA Health Plan Measure Concept Advisory Group agreed to move the heart failure concept forward for public comment. Comments received further supported the recommendation to advance the heart failure measure concept for development.
PQA has drafted initial specifications, and the goal of the TEP will be to support full specification of the measure concept and advancement to the PQA Quality Metrics Expert Panel for review prior to testing and subsequent steps in PQA’s standard measure development process.
Visit the PQA Measure Life Cycle page to learn more about developing measures that matter.
The TEP members are:
- Jacqueline D. Alikhaani, PCORI and WomenHeart (representing patients, caregivers and patient advocates)
- Ryan Bernstein, Rex Wallace Consulting, LLC
- Kristine Carrasco, MedImpact Healthcare Systems
- Michael Dorsch, University of Michigan College of Pharmacy
- Gerry Langan (representing patients and patient advocates)
- Melinda Morgan, UPMC Health Plan
- Rosalyn Otting, PQS by Innovaccer
- Amanda Place, ASHP
- Katherine Pleasants, CMS
- Glenda Sexauer, WomenHeart (representing patient and patient advocates)
- Meredith Sigler, VA North and Texas Tech University Health Sciences Center
- Jessica Szekely, Prime Therapeutics, LLC
- Christie Teigland, Inovalon
- Michelle Thompson, CVS Health
- Kyle Thorner, Devoted Health
- Joseph Van Tuyl, St. Louis College of Pharmacy at UHSP
- Landon Weaver, BlueCross BlueShield of Minnesota
- Ann Wild, MedWatchers